On May 23, 2018 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or resistant forms of cancer, reported that Judith Greciet, the Company’s Chief Executive Officer, will present at the 25th BIO International Convention (Press release, Onxeo, MAY 23, 2018, View Source [SID1234526866]). The conference is being held on June 4-7, 2018, in Boston, MA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). It is attended by more than 1,100 biotechnology and pharmaceutical companies, academic institutions, state biotechnology centers and related organizations across the United States and from over 30 countries worldwide.
Onxeo corporate presentation:
Date: June 4th, 2018
Time: 3 pm EST / 9 pm CEST
Location: Theater 2 – Boston Convention & Exhibition Center: 415 Summer St., Boston, MA
180523_ONXEO_PR_EN_BIO